We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
60 result(s) found, displaying 1 to 10
-
Oct-2025Prescription medicine evaluationActive ingredient: odevixibat, odevixibat sesquihydrate.
-
-
Australian public assessment report (AusPar)IQIRVO (elafibranor) is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
-
Australian public assessment report (AusPar)RELFYDESS (relabotulinumtoxinA) is for the temporary improvement in the appearance of moderate to severe glabellar lines at maximum frown and of moderate to severe lateral canthal lines seen at maximum smile.
-
Australian public assessment report (AusPar)BYLVAY (odevixibat) is for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older.
-
Prescription medicine registrationActive ingredients: cabozantinib (S)-malate.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BYLVAY odevixibat 200 microgram capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BYLVAY odevixibat 400 microgram capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BYLVAY odevixibat 600 microgram capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BYLVAY odevixibat 1200 microgram capsule bottle.